Boots, Johannes M. M. http://orcid.org/0000-0001-7922-7838
Quax, Rogier A. M.
Article History
Accepted: 19 July 2022
First Online: 6 September 2022
Declarations
:
: This was a physician-driven report and no funding was received.
: This manuscript follows all ethical considerations as proposed by the World Health Organization.
: Johannes M.M. Boots received lecture fees and participated in advisory boards from Cablon Medical, The Netherlands; Pharmacosmos, Denmark; and Vifor Pharma, The Netherlands. Rogier A.M. Quax has no disclosures with regard to this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: The literature was partly taken from a previous publication. We conducted a search of Pubmed for additional literature on specific items to prove our message. In addition, the literature was recognized from references from trials and reviews. We tried to check opinions in reviews as much as possible by analyzing original reports. It was not intended to review all possible literature, since many reports reached the same conclusions and therefore not all reports are incorporated in this manuscript.
: Not applicable.
: This report is driven by the recognition that physicians in clinical practice do not always make a proper risk–benefit analysis when prescribing intravenous iron formulations. Many physicians from diverse specialties, such as internal medicine, gastroenterology, geriatrics, rheumatology, cardiology, gynecology, and even pediatrics, are unaware of the possible adverse effects and may harm their patients. It is intended to develop a practical guideline, based on a thorough evaluation of the literature, which can be implemented in daily practice or electronic prescription modules to prevent further harm in the future. Both authors contributed to the literature search, writing of the manuscript, and designing the figures, and read and approved the final version.